Patients with EGFR-mutant lung cancer (a disease with 20,000 new diagnoses per year) derive significant clinical benefit from drugs that target the abnormal EGFR protein found in their tumors. My research focuses on: 1.) discovering the reasons why these tumors eventually develop resistance to EGFR-targeting drugs, and 2.) developing novel strategies to overcome or circumvent drug resistance.
Post-doctoral Research Fellow, Lovly Lab